Noiiglutide
Sources
registry, as of 2022-03-15Stale
https://clinicaltrials.gov/study/NCT06649773
The Experiment of Noiiglutide Injection in Type 2 Diabetes Patients. Overall status COMPLETED. Phases PHASE3. Lead sponsor Jiangsu HengRui Medicine Co., Ltd.. Enrollment 137. Conditions Type 2 Diabetes. This study aims to confirm that SHR20004 is more effective than placebo in controlling blood glucose in patients with type 2 diabetes. Evaluate the efficacy, safety, and pharmacokinetics of SHR20004 after 24 weeks of treatment.
ClinicalTrials.gov NCT06649773 protocol and results modules
registry, as of 2022-11-07Stale
https://clinicaltrials.gov/study/NCT03848793
A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.. Overall status COMPLETED. Phases PHASE2. Lead sponsor Jiangsu HengRui Medicine Co., Ltd.. Enrollment 128. Conditions Diabetes Mellitus, Type 2. The study is being conducted to evaluate the efficacy and safety of Noiiglutide Injection as mono-therapy with different doses in subjects with type 2 diabetes compared to placebo for 16 weeks.
ClinicalTrials.gov NCT03848793 protocol and results modules
registry, as of 2022-03-15Stale
https://clinicaltrials.gov/study/NCT04799327
The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without Diabetes. Overall status UNKNOWN. Phases PHASE2. Lead sponsor Jiangsu HengRui Medicine Co., Ltd.. Enrollment 254. Conditions Obesity. The study is being conducted to assess the efficacy and safety of SHR20004 on body weight in obese subjects without diabetes.
ClinicalTrials.gov NCT04799327 protocol and results modules